- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06064266
Healthy Fat, Happy Microbiome (TAPIR), Proof-of-Concept Study (TAPIR)
Rationale: The role of dietary lipids in host-microbiome research has for a long time been overlooked; as high lipid intake has been recently indicated to have the most pronounced effect on the small intestinal microbiome, fecal-oriented studies might have missed their important, local effect. Indications for an interaction between dietary lipids and the small intestinal microbiome are mainly based on animal studies, but human data are largely missing. This study therefore aims at exploring this principal in vivo in healthy individuals.
Primary objective: To assess the effect of dietary lipids on the small intestinal microbiome in humans (proof-of-concept), the primary objective of our study is to measure production of microbiota-derived lipid metabolites in the human small intestine after consumption of a plant-based high-fat shake in healthy pre-conditioned subjects.
Secondary objectives: To explore future perspectives for dietary lipid - small intestinal microbiome interactive research, the secondary objectives of our study are
- To compare the levels of microbiota-derived lipid metabolites in aspirate samples obtained through a naso-intestinal catheter (golden standard; invasive sampling method) and an aspiration capsule (less invasive, innovative sampling method), and in blood (local versus systemic effect) and feces (small intestinal versus fecal effect; less invasive sampling);
- To investigate the acute effect of a high-fat shake on the composition and transcriptome activity of the small intestine microbiota in aspirate samples of healthy pre-conditioned subjects; 2a) To compare the acute effects on the small intestine microbiota composition in aspirate samples obtained through a naso-intestinal catheter versus those obtained via an aspiration capsule;
- To study and compare the effect of a 8-day plant-based mild ketogenic preconditioning diet on the composition of the small intestine microbiota (aspiration capsule) and the fecal microbiota.
Study design: Proof-of-concept intervention study
Study population: 16 healthy adults, BMI between 18.5-30 kg/m2.
Intervention: 8-days preconditioning mild ketogenic controlled diet followed by a high fat shake challenge with a naso-intestinal catheter.
Main study parameters/endpoints: The primary study parameters are the microbial-derived metabolites from linoleic acid and plant sterols after consumption of the high fat shake.
Secondary study parameters include microbiota composition and transcriptome activity. Other parameters include inflammatory markers and ex-vivo analyses.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mara van Trijp, PhD
- Phone Number: + 31 (0) 317 48 67 39
- Email: mara.vantrijp@wur.nl
Study Contact Backup
- Name: Lonneke Janssen Duijghuijsen, PhD
- Email: lonneke.janssenduijghuijsen@wur.nl
Study Locations
-
-
Gelderland
-
Wageningen, Gelderland, Netherlands, 6708WE
- Wageningen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult male or female
- BMI 18.5-30 kg/m2
- Suitable veins for insertion of cannula
Exclusion Criteria:
- Having a history of medical or surgical events that may either put the subject at risk because of participation in the study, or influence the results of the study, including diabetes mellitus, dyslipidemia, a swallowing disorder, gastrointestinal or liver disease, irritable bowel syndrome, sleeping apnea, renal failure, cancer, nose/throat diseases, gastric bypass surgery, use of anticoagulants; as determined by the medical supervisor;
- Having a bleeding/coagulation disorder, including hemophilia, Von Willebrand disease, Bernard-Soulier, Glanzmann thrombasthenia or thrombocytopenia;
- Use of antibiotics within 3 months of starting the study or planned during the study;
- Use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA), as determined by medical supervisor;
- Use of pro- and prebiotic supplements within 4 weeks of starting the study;
- Planning or scheduled to undergo magnetic resonance imaging (MRI) at any time during the course of the study (the SIMBA Capsule is MR unsafe)
- Currently following a very low carbohydrate (ketogenic) diet;
- Having regularly less than 3 bowel movements per week (being constipated);
- Alcohol consumption >21 glasses a week (women) or >28 glasses a week (men);
- Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported);
- Not willing to give up blood donation during the study;
- Food allergies or intolerances for products that we use in the study;
- Current smokers;
- Current users of soft and/or hard drugs;
- Participation in another clinical trial at the same time;
- Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research or Human Nutrition and Health Department of Wageningen University.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 8-days plant-based preconditioning mild ketogenic controlled diet followed by a high-fat shake.
|
Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lipid metabolites from linoleic acid and plant sterols in the small intestine aspirates
Time Frame: 0-6 hours
|
Concentrations of microbiota-derived lipid metabolites in the small intestine aspirates, obtained by a naso-intestinal catheter, measured by lipidomics.
|
0-6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lipid metabolites in small intestine aspirate samples obtained with an aspiration capsule.
Time Frame: 0-6 hours
|
Concentrations of microbiota-derived lipid metabolites in the small intestine aspirates, obtained by an aspiration capsule, measured by lipidomics.
|
0-6 hours
|
small intestine microbiota composition
Time Frame: 0-6 hours
|
The relative composition (%) of the small intestine microbiota in aspirate samples obtained by an intestinal catheter.
|
0-6 hours
|
small intestine microbiome capacity
Time Frame: 0-6 hours
|
The functional capacity (transcriptomic activity) of the small intestine microbiota in aspirate samples obtained by an intestinal catheter.
|
0-6 hours
|
Faecal microbiota
Time Frame: Baseline, after 8 days.
|
The relative composition (%) of the faecal microbiota
|
Baseline, after 8 days.
|
Blood lipid metabolites
Time Frame: 0-6 hours
|
Lipid metabolites (HYA, CLA, all untargeted lipid metabolites) will be measured in blood samples with lipidomics.
|
0-6 hours
|
Blood triglycerides
Time Frame: 0-6 hours
|
Concentrations of triglycerides
|
0-6 hours
|
Blood free fatty acids
Time Frame: 0-6 hours
|
Concentrations of free fatty acids
|
0-6 hours
|
small intestine microbiota
Time Frame: Baseline, after 5 days.
|
The relative composition (%) of the small intestine microbiota in aspirates obtained by an aspiration capsule.
|
Baseline, after 5 days.
|
small intestine microbiome
Time Frame: Baseline, after 5 days.
|
The functional capacity (transcriptomic activity) of the small intestine microbiota in aspirates obtained by an aspiration capsule.
|
Baseline, after 5 days.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood LPS
Time Frame: 0-6 hours
|
0-6 hours
|
Blood ApoB48
Time Frame: 0-6 hours
|
0-6 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NL81345.081.23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Intestine
-
Medtronic - MITGRecruitingSmall Intestine Cancer | Small Intestine Adenocarcinoma | Small Intestine Disease | Small Intestinal Ulcer Bleeding | Small Intestine Obstruction | Small Intestine PolypUnited States
-
Medtronic - MITGNot yet recruitingSmall Intestine Cancer | Small Intestine Adenocarcinoma | Small Intestine Disease | Small Intestinal Ulcer Bleeding | Small Intestine Obstruction | Small Intestine Polyp
-
Lawson Health Research InstituteCompleted
-
United Lincolnshire Hospitals NHS TrustUnknownSmall Intestine Problem
-
Mayo ClinicIcahn School of Medicine at Mount Sinai; Imperial College London; University... and other collaboratorsCompletedSmall Intestine BacteriaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Sanofi; PfizerCompletedRecurrent Small Intestine Cancer | Small Intestine AdenocarcinomaUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIICompleted
-
Changhai HospitalChinese PLA General HospitalRecruitingStomach Diseases | Small Intestine DiseaseChina
-
CHU de ReimsUnknownSuspicion of Tumor of the Small IntestineFrance
-
NIZO Food ResearchWageningen UniversityCompletedMicrobiota Composition in the Human Small IntestineNetherlands
Clinical Trials on plant-based mild ketogenic controlled diet
-
University of MinnesotaCompleted
-
Montefiore Medical CenterThe Purjes Foundation; The Greenbaum FoundationRecruiting
-
Taipei Veterans General Hospital, TaiwanRecruiting
-
George Washington UniversityNot yet recruitingInflammation | Hypertension | Diabetes Mellitus | Metabolic Syndrome | Dietary Habits | Kidney Disease, Chronic | Kidney Transplant Failure | Transplant Complication
-
Mayo ClinicCompleted
-
Charite University, Berlin, GermanyCharite University, Department for Dental MedicineCompletedMetabolic Syndrome | Overweight and Obesity | Cardiovascular Risk Factor | Hypertension,EssentialGermany
-
University of UlsterFondazione Edmund MachCompletedMicrobiota | Nutrition, HealthyUnited Kingdom
-
Vanderbilt University Medical CenterSeth BordensteinCompletedDiet Modification | Microbial ColonizationUnited States
-
Vascular Institute of TexasUnknownPeripheral Arterial DiseaseUnited States
-
Physicians Committee for Responsible MedicineRecruiting